Lophora is a clinical-stage CNS drug discovery company developing novel, next-generation neuroplasticity inducing medicines to treat underserved mood and anxiety disorders. www.lophora.com Founded in 2018 Lophora has successfully finished initial characterization of its lead-candidate LPH-5 through funding granted by the BII (Novo Nordisk Foundation), public funds and experienced biotech investors. Lophora will initiate first-in-human trials by 2024. Efficacy of LPH-5 has been extensively characterized in vivo and has successfully completed GLP-Tox with expected CTA submission by Q2 2024.
| Website | http://www.lophora.com |
| Employees | 8 (3 on RocketReach) |
| Founded | 2018 |
| Industry | Biotechnology Research, Manufacturing General, Manufacturing |
| Keywords | Clinical Stage Drug Development, Novel Therapeutics, Brain Health, Drug Development, Biopharmaceutical Research, Psychedelic Therapy, Neurological Disorders, Pharmaceutical Research, Clinical Trials, Drug Discovery, Biotechnology, Innovative Medicines, Medicine Development, Healthcare, Therapeutics |
| Competitors | Johnson & Johnson, Pfizer, Sanofi, GSK, AstraZeneca, Regeneron, Moderna Therapeutics, Novavax, CureVac, INOVIO Pharmaceuticals, Inc. +41 more (view full list) |
| SIC | SIC Code 283 Companies, SIC Code 2834 Companies, SIC Code 28 Companies |
| NAICS | NAICS Code 3254 Companies, NAICS Code 32541 Companies, NAICS Code 32 Companies, NAICS Code 325 Companies |
Looking for a particular Lophora employee's phone or email?
Bo Tandrup is the Co-founder and CEO of Lophora.
3 people are employed at Lophora.
The NAICS codes for Lophora are [3254, 32541, 32, 325].
The SIC codes for Lophora are [283, 2834, 28].